Pfizer’s Quiet Upswing: Defensive Gains, Strong Oncology, and Rising Value‑Based Focus
Pfizer’s share rise shows resilient earnings and a growing oncology pipeline—key insights for investors navigating value‑based pricing and AI‑driven drug discovery.
5 minutes to read


